3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 2
2
Phase 1/2
2
Status
Withdrawn
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Colorectal Neoplasms
220
Rectal Neoplasms
137
Stomach Neoplasms
95
Colonic Neoplasms
87
Pancreatic Neoplasms
82
Esophageal Neoplasms
71
Neoplasm Metastasis
58
Squamous Cell Carcinoma of Head and Neck
43
Head and Neck Neoplasms
42
Adenocarcinoma Of Esophagus
37
Neoplasms
36
Breast Neoplasms
35
Esophageal Squamous Cell Carcinoma
27
Carcinoma, Hepatocellular
22
Cholangiocarcinoma
21
Adenocarcinoma
17
Nasopharyngeal Carcinoma
16
Bile Duct Neoplasms
14
Gallbladder Neoplasms
13
Carcinoma, Squamous Cell
13
Biliary Tract Neoplasms
13
Anus Neoplasms
13
Urinary Bladder Neoplasms
11
Liver Neoplasms
10
Carcinoma
9
Nasopharyngeal Neoplasms
8
Colorectal Cancer Metastatic
8
Peritoneal Neoplasms
7
Recurrence
6
Ovarian Neoplasms
6
Interventions
Carboplatin
79
pembrolizumab
64
Paclitaxel
64
Cyclophosphamide
47
Capecitabine
34
Doxorubicin
31
Taxes
28
130-nm albumin-bound paclitaxel
28
Albumin-Bound Paclitaxel
27
Gemcitabine
20
atezolizumab
18
Epirubicin
18
Cisplatin
18
Bevacizumab
18
olaparib
17
sacituzumab govitecan
15
Docetaxel
15
eribulin
14
toripalimab
13
durvalumab
13
camrelizumab
13
Drug Therapy
12
apatinib
9
Trastuzumab
9
Radiotherapy
9
Specimen Handling
8
Magnetic Resonance Spectroscopy
8
Biopsy
8
tislelizumab
7
talazoparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Triple Negative Breast Neoplasms
×
Fluorouracil
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled
NCT03554109
2025-02-21
TNBC
ImmunityBio, Inc.
Phase 2
Withdrawn